Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI)

被引：6

作者：

Ding, Hong-hua ^{[1
]}

Wu, Wei-dong ^{[2
]}

Jiang, Tao ^{[2
]}

Cao, Jun ^{[2
]}

Ji, Zheng-yi ^{[2
]}

Jin, Jia-huan ^{[1
]}

Wang, Jing-jue ^{[1
]}

Song, Wei-feng ^{[1
]}

Wang, Li-wei ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Oncol, Shanghai 200080, Peoples R China

[2] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Sch Med, Dept Surg, Shanghai 200080, Peoples R China

来源：

TUMOR BIOLOGY | 2015年 / 36卷 / 05期

关键词：

CAPIRI; FOLFIRI; Metastatic colorectal cancer; Meta-analysis; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; ORAL CAPECITABINE; BEVACIZUMAB; FLUOROURACIL; COMBINATION; LEUCOVORIN; TRIAL; ACID;

D O I：

10.1007/s13277-014-2970-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined. We identified and subsequently examined seven independent, randomized controlled clinical trials, performing a meta-analysis to compare these two treatment regimens. Using Medline, EMBASE, Cochrane Library (CENTRAL), and the American Society of Clinical Oncology Annual Meeting to search available literature until February 2014, we identified seven studies comparing safety and efficacy of CAPIRI and FOLFIRI in mCRC patients. These studies were pooled and evaluated for rates of progression-free survival (PFS), objective response rate (ORR), overall survival (OS), and diarrhea. CAPIRI and FOLFIRI demonstrated similar efficacy outcomes, though CAPIRI was associated with a higher incidence of diarrhea. CAPIRI and FOLFIRI are equally effective options for first-line treatment of mCRC.

引用

页码：3361 / 3369

页数：9

共 23 条

[1]

[Anonymous], 2006, Cochrane Handbook for Systematic Reviews of Interventions

[2] Management of advanced colorectal cancer, part 1 [J].

Cersosimo, Robert J. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (05) :395-406

[3] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[4] Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) [J].

Ducreux, M. ;

Adenis, A. ;

Pignon, J. -P. ;

Francois, E. ;

Chauffert, B. ;

Ichante, J. L. ;

Boucher, E. ;

Ychou, M. ;

Pierga, J. -Y. ;

Montoto-Grillot, C. ;

Conroy, T. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) :1236-1245

[5]

Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357

[6] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].

Hoff, PM ;

Ansari, R ;

Batist, G ;

Cox, J ;

Kocha, W ;

Kuperminc, M ;

Maroun, J ;

Walde, D ;

Weaver, C ;

Harrison, E ;

Burger, HU ;

Osterwalder, B ;

Wang, AO ;

Wong, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292

[7]

Howlader N, SEER CANC STAT REV 1

[8] Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.: EORTC study 40015 [J].

Koehne, C.-H. ;

De Greve, J. ;

Hartmann, J. T. ;

Lang, I. ;

Vergauwe, P. ;

Becker, K. ;

Braumann, D. ;

Joosens, E. ;

Mueller, L. ;

Janssens, J. ;

Bokemeyer, C. ;

Reimer, P. ;

Link, H. ;

Spath-Schwalbe, E. ;

Wilke, H. -J. ;

Bleiberg, H. ;

Van den Brande, J. ;

Debois, M. ;

Bethe, U. ;

Van Cutsem, E. .

ANNALS OF ONCOLOGY, 2008, 19 (05) :920-926

[9] Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial [J].

Koopman, Miriam ;

Antonini, Ninja F. ;

Douma, Joep ;

Wals, Jaap ;

Honkoop, Aafke H. ;

Erdkamp, Frans L. G. ;

de Jong, Robert S. ;

Rodenburg, Cees J. ;

Vreugdenhil, Gerard ;

Loosveld, Olaf J. L. ;

van Bochove, Aart ;

Sinnige, Harm A. M. ;

Creemers, Geert-Jan M. ;

Tesselaar, Margot E. T. ;

Slee, Peter H. Th J. ;

Werter, Marjon J. B. P. ;

Mol, Linda ;

Dalesio, Otilia ;

Punt, Cornelis J. A. .

LANCET, 2007, 370 (9582) :135-142

[10] Advances in the Treatment of Metastatic Colorectal Cancer [J].

Kurkjian, Carla ;

Kummar, Shivaani .

AMERICAN JOURNAL OF THERAPEUTICS, 2009, 16 (05) :412-420

← 1 2 3 →